Engineered Proteins for Targeted Full Spectrum Influenza Neutralization

Exclusively Licensed

The present invention provides novel agents for broad spectrum influenza neutralization. The present invention provides agents for inhibiting influenza infection by bind to the influenza virus and/or hemagglutinin (HA) polypeptides and/or HA receptors, and reagents and methods relating thereto. The present invention provides a system for analyzing interactions between infolds and the interaction partners that bind to them.

Researchers

Ram Sasisekharan / Vidya Subramanian / Venkataramanan Soundararajan / Karthik Viswanathan / Sasisekharan Raguram / Viswanathan Sasisekharan

Departments: School of Engineering
Technology Areas: Drug Discovery and Research Tools: Antibodies / Therapeutics: Proteins & Antibodies
Impact Areas: Healthy Living

  • engineered polypeptide agents for targeted broad spectrum influenza neutralization
    Japan | Published application
  • engineered polypeptide agents for targeted broad spectrum influenza neutralization
    United States of America | Granted | 8,637,456
  • engineered polypeptide agents for targeted broad spectrum influenza neutralization
    European Patent Convention | Granted | 2,528,615
  • engineered polypeptide agents for targeted broad spectrum influenza neutralization
    Japan | Granted | 6,210,685
  • engineered polypeptide agents for targeted broad spectrum influenza neutralization
    Canada | Granted | 2,787,940
  • engineered polypeptide agents for targeted broad spectrum influenza neutralization
    Australia | Granted | 2,011,210,840
  • engineered polypeptide agents for targeted broad spectrum influenza neutralization
    United States of America | Granted | 9,334,309
  • engineered polypeptide agents for targeted broad spectrum influenza neutralization
    Japan | Published application
  • engineered polypeptide agents for targeted broad spectrum influenza neutralization
    United States of America | Granted | 9,572,861
  • engineered polypeptide agents for targeted broad spectrum influenza neutralization
    Germany | Granted | 2,528,615
  • engineered polypeptide agents for targeted broad spectrum influenza neutralization
    Spain | Granted | 2,528,615
  • engineered polypeptide agents for targeted broad spectrum influenza neutralization
    France | Granted | 2,528,615
  • engineered polypeptide agents for targeted broad spectrum influenza neutralization
    United Kingdom | Granted | 2,528,615
  • engineered polypeptide agents for targeted broad spectrum influenza neutralization
    Italy | Granted | 2,528,615

License this technology

Interested in this technology? Connect with our experienced licensing team to initiate the process.

Sign up for technology updates

Sign up now to receive the latest updates on cutting-edge technologies and innovations.

More Technologies